search
Back to results

Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis

Primary Purpose

Intrauterine Adhesion

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
disposable balloon uterine stent
dried biological amnion graft
estradiol valerate tablets+dydrogesterone tablets
Sponsored by
Beijing Obstetrics and Gynecology Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Intrauterine Adhesion focused on measuring Asherman syndrome, hysteroscopy, Uterine stent, Estrogen, Amnion, Hysteroscopic Adhesiolysis

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • age 20-40 years;
  • previously diagnostic hysteroscopy confirmed adhesion score >5, according to the American Fertility Society (AFS)classification of IUA;
  • complains of menstruation disorder and reproductive dysfunction;
  • informed consent.

Exclusion Criteria:

  • premature menopause,
  • presence of other intrauterine lesions (e.g. polyps, myoma, septa), and
  • presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases),
  • adhesions limited to the lower uterine cavity or the cervical canal.

Sites / Locations

  • Beijing Obstetrics and Gynecology Hospital,Capital Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

dried biological amnion graft

estrogen

Arm Description

patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.

patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.

Outcomes

Primary Outcome Measures

Incidence of adhesion information
Intrauterine adhesions under hysteroscopy

Secondary Outcome Measures

Menstruation pattern
menstrual volume which was assessed by pictorial blood loss assessment chart
The change of AFS score
The American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.

Full Information

First Posted
November 14, 2017
Last Updated
November 17, 2017
Sponsor
Beijing Obstetrics and Gynecology Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03346317
Brief Title
Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis
Official Title
Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft for the Therapy of Uterine Adhesion
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 16, 2017 (Actual)
Primary Completion Date
May 16, 2018 (Anticipated)
Study Completion Date
May 20, 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Beijing Obstetrics and Gynecology Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. The recurrence of intrauterine adhesions is a major challenge in clinical practice. It has been reported that dried biological aminion graft was used to prevent adhesion after the operation of intrauterine adhesions. Estrogen is also used for postoperative prevention of intrauterine adhesions. Intrauterine balloon can reduce the recurrence of adhesions after operation. Does the combination of balloon with amniotic products or estrogen can improve clinical outcomes? Therefore, this study was conducted.
Detailed Description
Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double (participant and outcomes Assessor) Primary Purpose: Prevention

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intrauterine Adhesion
Keywords
Asherman syndrome, hysteroscopy, Uterine stent, Estrogen, Amnion, Hysteroscopic Adhesiolysis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
dried biological amnion graft
Arm Type
Experimental
Arm Description
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
Arm Title
estrogen
Arm Type
Experimental
Arm Description
patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
Intervention Type
Device
Intervention Name(s)
disposable balloon uterine stent
Intervention Description
The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
Intervention Type
Procedure
Intervention Name(s)
dried biological amnion graft
Intervention Description
Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
Intervention Type
Drug
Intervention Name(s)
estradiol valerate tablets+dydrogesterone tablets
Other Intervention Name(s)
Progynova+dydrogesterone
Intervention Description
oral estradiol valerate tablets+dydrogesterone tablets
Primary Outcome Measure Information:
Title
Incidence of adhesion information
Description
Intrauterine adhesions under hysteroscopy
Time Frame
Within the first 3 months after surgery
Secondary Outcome Measure Information:
Title
Menstruation pattern
Description
menstrual volume which was assessed by pictorial blood loss assessment chart
Time Frame
Within the first 3 months after surgery
Title
The change of AFS score
Description
The American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.
Time Frame
Within the first 3 months after surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age 20-40 years; previously diagnostic hysteroscopy confirmed adhesion score >5, according to the American Fertility Society (AFS)classification of IUA; complains of menstruation disorder and reproductive dysfunction; informed consent. Exclusion Criteria: premature menopause, presence of other intrauterine lesions (e.g. polyps, myoma, septa), and presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases), adhesions limited to the lower uterine cavity or the cervical canal.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhu Ru, MD
Phone
13966636438
Email
zhuru19790202@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Wang Sha, MD
Phone
15201556908
Email
wangsha1020@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Duan Hua, PhD
Organizational Affiliation
Beijing Obstetrics and Gynecology Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Beijing Obstetrics and Gynecology Hospital,Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liu Zhen
Phone
+8613718210767
Email
fcyykyb@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis

We'll reach out to this number within 24 hrs